Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Combined FDG-PET/CT In Response Evaluation Of Malignant Pleural Mesothelioma.

P. Veit-Haibach, N. Schaefer, H. Steinert, J. Soyka, B. Seifert, R. Stahel
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE Based on the complex growth pattern of MPM, conventional response evaluation in this cancer entity is challenging. Therefore, there is growing interest in therapy response evaluation with FDG-PET/CT. The aim of the study was to evaluate the value of several FDG-PET/CT-parameters in therapy response evaluation concerning prediction of survival at baseline and after three cycles of therapy. PATIENTS AND METHODS The study was performed in accordance with the regulations of the local ethics committee. Forty-one patients with proven MPM and treated with palliative pemetrexed and platinum-based chemotherapy were included. All patients were evaluated by FDG-PET/CT at baseline and after three cycles of chemotherapy. Responders and non-responders were evaluated based on modified RECIST- and EORTC-criteria. Additional PET-parameters (SUVmean, tumor lesion glycolysis (TLG) and tumor volume (PETvol)) were evaluated. Results were evaluated using the COX regression and the Kaplan-Meier method. RESULTS None of the baseline CT-measurements or the initial PET-parameters were predictive for survival. Based on CT, after three cycles of therapy 10 patients were categorized as responders, 30 were classified as stable disease and 1 had progressive disease. Based on PET-evaluation, 14 responders were identified, 23 patients with stable disease and 4 patients were progressive. CT-response after 3 cycles of chemotherapy was significantly related to overall survival (p=0.001). However, neither SUVmax-response (p=0.61) nor SUVmean-response (p=0.68) were related to survival. A decrease of TLG and PETvol, however, was found to be predictive (TLG: p=0.01; PETvol: p=0.002). CONCLUSION Response evaluation based on modified RECIST by CT as well as response evaluation by TLG and PETvol in FDG-PET, but not SUVmax-measurements are predictive for survival in MPM.
This paper references
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1093/annonc/mdj912
Malignant pleural mesothelioma.
P. Baas (1998)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1016/J.LUNGCAN.2007.05.015
False positive 18F-FDG-PET/CT in a patient after talc pleurodesis.
H. Ahmadzadehfar (2007)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1378/CHEST.125.6.2356
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1007/s11605-007-0170-7
Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy
G. Melton (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1016/S1095-0397(00)00041-8
Tumor Burden Assessment with Positron Emission Tomography with
Akhurst (2000)
10.1016/S1095-0397(99)00016-3
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
S. Larson (1999)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1093/emboj/18.7.1824
Oncogenic Ras inhibits Fas ligand‐mediated apoptosis by downregulating the expression of Fas
J. Peli (1999)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)



This paper is referenced by
10.1016/j.jtho.2018.04.034
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
A Multimodality Imaging Review of Malignant Pleural Mesothelioma Assessment
A. Nowak (2011)
Comparison of Threshold-Based Segmentation Methods on Pre- and Post-Therapy PET Scans
M. Phillips (2014)
10.1097/MNM.0000000000000395
Determinants of diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin
A. V. Pereira (2016)
10.1007/s00330-016-4264-z
Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma
J. Lee (2016)
10.1007/s11307-010-0426-6
Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment
S. Basu (2010)
10.1097/JTO.0B013E3182370E7E
Reply to the Letter to the Editor Entitled A Practical Guide to Measure “All” Malignant Pleural Mesothelioma Tumors by Modified RECIST Criteria?
A. Tsao (2011)
10.1967/s002449910904
18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
A. Niccoli Asabella (2018)
10.1007/978-3-030-16884-1_10
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
10.1016/j.ejrad.2016.11.009
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Shingo Kanemura (2017)
10.1016/j.clinimag.2011.09.007
Elevated uptake of 18F-FDG in PET/CT imaging of a nocardial pleural nodule.
K. Zhao (2012)
10.1016/J.JARE.2011.02.004
European guidelines for the management of malignant pleural mesothelioma
E. Thiel (2011)
10.1016/j.ejrad.2010.11.006
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
N. Schaefer (2012)
10.1967/s002449910162
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
V. A. Marín-Oyaga (2015)
Guidelines for the Clinical Use of 18 F-FDG-PET/MRI 2012 (Ver 1.0): Part 2
U. Tateishi (2012)
Clinical implications of 18 F-fluorodeoxyglucose positron emission tomography / computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma
Y. Abe (2011)
10.1097/JTO.0b013e318236e3af
The role of postoperative radiotherapy after resection of stage III thymoma.
M. Anile (2011)
10.1016/j.clinimag.2016.05.001
Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
B. Schaarschmidt (2016)
10.1016/j.lungcan.2013.11.004
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
10.1007/s00259-014-2960-y
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
10.1097/MNM.0000000000000789
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma
D. Hall (2018)
10.7150/jca.2586
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy
G. Genestreti (2012)
10.1007/s00330-016-4368-5
Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer
M. Lee (2016)
10.1007/s10266-018-0379-9
Correlation between the malignancy and prognosis of oral squamous cell carcinoma in the maximum standardized uptake value
O. Hasegawa (2018)
10.21037/atm.2017.05.23
Volumetric assessment in malignant pleural mesothelioma.
D. Murphy (2017)
10.2967/jnumed.119.238733
18F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume
J. Reynolds (2020)
10.1007/s00280-017-3411-9
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review
J. Kim (2017)
10.1007/s00259-018-4056-6
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients
E. Incerti (2018)
10.5152/tcb.2015.062
Therapy Response Evaluation With Fdg-Pet/Ct In Thoracic Malignancies
Z. G. Ozkan (2015)
10.1016/j.revmed.2014.10.360
[Pleural effusion: diagnosis and management].
J. Pastré (2015)
10.1002/cam4.1182
Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
P. Zucali (2017)
10.1038/bjc.2015.62
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
C. Hooper (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar